SSRIs and Sexual Dysfunction: A Genetic and Pharmacogenomic Reappraisal in the Era of Precision Psychosexual Medicine

Sexual dysfunction (SD), encompassing reduced libido, anorgasmia, erectile difficulties, and genital numbness, is among the most frequently reported and distressing adverse effects associated with Selective Serotonin Reuptake Inhibitor (SSRIs), affecting both quality of life and long-term medication adherence, with prevalence rates ranging from 30% to 70% during treatment and cases of lingering symptoms even after discontinuation, termed post-SSRI SD. ¹ Symptoms include reduced libido, anorgasmia, erectile difficulties, and genital numbness. The psychological burden associated with SD affects not only personal relationships but also adherence to antidepressant regimens, necessitating robust, mechanism-based interventions. ² At the time, studies were limited, largely exploratory, and lacked integration with real-world clinical practice. Over the past decade, the landscape of psychosexual health has shifted dramatically, shaped by advancements in pharmacogenomics. ³ For example, mobile applications and wearable devices that track sexual activity, mood, and medication adherence are increasingly being integrated into real-world psychopharmacology studies. ⁴

SD remains a significant barrier to antidepressant adherence, with contemporary estimates affirming that 30%–60% of SSRI users experience persistent SD. ⁵ Significantly, while early studies focused on Cytochrome P450 2D6 (CYP2D6), 5-Hydroxytryptamine Receptor 2A (HTR2A), Solute Carrier Family 6 Member 4 (Serotonin Transporter Gene) (SLC6A4), and Brain-Derived Neurotrophic Factor (BDNF) variants, recent large-scale genome-wide association studies and multi-omics platforms have broadened the genetic spectrum.^6,7 Glutamatergic gene variants, including Glutamate Ionotropic Receptor Kainate Type Subunit 2 (GRIK2), Glutamate Ionotropic Receptor AMPA Type Subunit 3 (GRIA3), and Glutamate Ionotropic Receptor NMDA Type Subunit 3A (GRIN3A), originally identified in the Sequenced Treatment Alternatives to Relieve Depression cohort, have since been substantiated through polygenic risk models as influential predictors of SSRI tolerability and side-effect susceptibility, including SD. ⁸ Moreover, variants in μ-opioid receptor, ⁹ estrogen receptor, ¹⁰ and androgen receptor have been identified as additional contributors to the modulation of sex hormone effects on antidepressant side effects.

What has particularly evolved is the recognition of gender-specific and hormonal influences on SSRI response. ¹¹ Recent pharmacogenetic evidence indicates that interactions between SSRI pharmacodynamics and oral contraceptive use, estrogen signaling, and Hypothalamic–Pituitary–Adrenal (HPA) axis sensitivity may modulate female-specific responses. ¹² Likewise, digital health platforms now allow for real-time tracking of sexual side effects and mood changes, which, when integrated with pharmacogenomic profiles, can offer a dynamic, precision medicine approach. ¹³ Additionally, the paradigm has shifted from viewing SD solely as an adverse event to recognizing a shared genetic liability between depression, sexual function, and SSRI response. This complexity necessitates a model that integrates genetic, hormonal, psychosocial, and neurobiological dimensions, a systems biology framework for psychosexual health. ¹⁴

As we revisit the insights from 2010, it becomes evident that the trajectory of research is moving from candidate-gene associations to polygenic and machine learning models, paving the way for individualized treatment strategies.^15,16 The integration of pharmacogenomic testing in clinical psychiatry is no longer aspirational but increasingly actionable, with commercial panels now incorporating SSRI-related genes into routine prescribing workflows. ¹⁷ These panels often include CYP2D6, CYP2C19, and SLC6A4, among others, helping psychiatrists make dose adjustments and select appropriate drugs. ¹⁸

We suggest future research and clinical practice to adopt a sex-informed, genome-guided approach to antidepressant therapy, particularly with respect to mitigating SD and reinforcing the clinical imperative for screening and early intervention. This includes proactive risk prediction, patient-centered counseling, and incorporation of genomic data into shared decision-making. Routine assessment of sexual health should be embedded into psychiatric care pathways, supported by genomic insights and patient-reported outcomes. As the Journal of Psychosexual Health continues to highlight the intersection of pharmacology and sexuality, this reappraisal of SSRI pharmacogenetics stands as both a reflection and a call to action for a new era of precision psychosexual medicine.